As a noncovalent inhibitor of BTK, pirtobrutinib is able to reestablish BTK inhibition in patients previously treated with covalent BTK inhibitors.
Diagnosis & Disease Information
Trial Evaluating Lisocabtagene Maraleucel for Relapsed/Refractory CLL Meets Endpoint
Lisocabtagene maraleucel is a CD19-directed genetically modified autologous T cell immunotherapy.
Brukinsa Gains Approval for Chronic Lymphocytic Leukemia
The approval was based on data from the phase 3 SEQUOIA and ALPINE studies in patients with CLL/SLL.
MPR Weekly Dose Podcast Episode #144
FDA grant accelerated approval to Alzheimer disease treatment; New fixed-dose asthma treatment; NERD therapy looks promising; Leukemia drug to be withdrawn in 2023; Pertussis prevention treatment approved for use during pregnancy.
AstraZeneca Will Withdraw Leukemia Drug Lumoxiti From US Market
Lumoxiti was approved by the FDA in September 2018 for the treatment of adults with relapsed or refractory hairy cell leukemia.
Lunsumio Approved for Relapsed or Refractory Follicular Lymphoma
Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody that targets CD20 on the surface of B cells and CD3 on the surface of T cells.
Rezlidhia Now Available for Relapsed/Refractory AML With IDH1 Mutation
Rezlidhia is a small molecule inhibitor of mutated IDH1.
